Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
04/26/2023 - 07:00 AM
TEL AVIV, Israel , April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2 – May 4, 2023 . Chemomab management will present a corporate overview on Wednesday, May 3, 2023 .
Aegis 2023 Virtual Investor Conference
In addition, Chemomab reported that its corporate development team will be in Boston June 5-8, 2023 , participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.
About Chemomab Therapeutics Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com .
Contacts:
Investors:
Investors & Media:
Irina Koffler
Barbara Lindheim
LifeSci Advisors, LLC
Chemomab Therapeutics
Phone: +1 (917) 734-7387
Consulting Vice President, Investor & Public Relations
ir@chemomab.com
Strategic Communications
barbara.lindheim@chemomab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-2023-aegis-virtual-conference-301807799.html
SOURCE Chemomab Therapeutics, Ltd.
Chemomab Therapeutics Ltd
CMMB Rankings
N/A Ranked by Stock Gains
CMMB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About CMMB
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).